Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,787 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intervention 2 - Sham Treatment Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects

NCT02654626
View directory record Official record
Conditions
Healthy
Interventions
KBP-7072, Placebo
Drug · Other
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

NCT07093008
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension
Drug
Lead sponsor
AQILION AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Selective Nerve Stimulation (SNS) Pilot Study

NCT01259271
View directory record Official record
Conditions
Healthy, Pain
Interventions
Selective Nerve Stimulation (SNS) stimulator device
Device
Lead sponsor
Codman & Shurtleff
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Raynham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 30, 2026, 9:02 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Modified Brostrӧm Procedure With and Without Possible Arthroscopy for Lateral Ankle Instability

NCT02470338
View directory record Official record
Conditions
Lateral Ankle Instability
Interventions
MBP plus arthroscopy (Group A), MBP alone (Group B)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate the Use of the Foundation Pain Index and the Nutritional Supplement BioPlete™ in Adults With Chronic Pain

NCT05278533
View directory record Official record
Conditions
Chronic Pain
Interventions
BioPlete™ Advanced Formula, Placebo
Dietary Supplement
Lead sponsor
Ethos Research & Development
Industry
Eligibility
30 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Tampa, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of TG100-115 for Heart Attack Treated With Angioplasty

NCT00103350
View directory record Official record
Conditions
Myocardial Infarction
Interventions
TG100-115
Drug
Lead sponsor
TargeGen
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Trial: Rapid Immune Modulating Effects

NCT07195552
View directory record Official record
Conditions
Immune Surveillance
Interventions
Agaricus blazei, Reishi, Turkey Tail, Placebo
Dietary Supplement · Other
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Effect of Supplement on Appetite and GLP-1

NCT06790771
View directory record Official record
Conditions
Hunger
Interventions
High Dose Supplement, Low Dose Supplement, Placebo
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

The Use of Functional Confections in Promoting Oral Health

NCT01514552
View directory record Official record
Conditions
Oral Health, Oral Cancer, Gum Disease
Interventions
Strawberry gummy, Placebo control gummy
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 30, 2026, 9:02 PM EDT
Terminated Phase 2 Interventional

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

NCT06617455
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Localized Breast Carcinoma
Interventions
Biospecimen Collection, Fezolinetant, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Blueberries, Inflammation, Motivation, and Physical Activity

NCT05735587
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Freeze-dried Blueberry Powder, Placebo Powder
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

Circadian Light Exposure Adjustment for Restfulness

NCT07391852
View directory record Official record
Conditions
Sleep Onset Latency
Interventions
Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs
Device
Lead sponsor
University of Arizona
Other
Eligibility
60 Months to 83 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT03418038
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions
Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography, Decitabine and Cedazuridine
Dietary Supplement · Drug · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
4
States / cities
Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

NCT06059391
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation Conditioning Regimen, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Pheresis, Placebo Administration, Stem Cell Mobilization Therapy
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Interpersonal Expectations on Negative Affect

NCT06980090
View directory record Official record
Conditions
Negative Affectivity, Non-invasive Brain Stimulation, Placebo Effect, Expectations
Interventions
Session A: Positive Placebo + Active tTIS, Session B: Positive Placebo + Sham tTIS, Session C: Negative Placebo + Active tTIS, Session D: Negative Placebo + Sham tTIS, Session E: On-Placebo + Sham tTIS, Session F: Off-Placebo + Sham tTIS
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 55 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)

NCT00590538
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sodium 4-Phenylbutyrate, Genistein (Unconjugated Isoflavones 100), Placebo
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

NCT00985517
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CERE-120: Adeno-Associated Virus Delivery of Neurturin, Sham Surgery
Biological · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
35 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

NCT00662363
View directory record Official record
Conditions
Constipation
Interventions
Lubiprostone, Senna
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

NCT04118387
View directory record Official record
Conditions
Sleep Disordered Breathing, Able Bodied
Interventions
Acetazolamide + supplemental oxygen + PAP therapy, Zolpidem + PAP therapy, Buspirone + PAP therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

NCT02686658
View directory record Official record
Conditions
Geographic Atrophy, Dry Age-Related Macular Degeneration
Interventions
Avacincaptad Pegol, Sham
Drug · Other
Lead sponsor
IVERIC bio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 30, 2026, 9:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

NCT04927585
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 30, 2026, 9:02 PM EDT
Recruiting Phase 1 Interventional

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

NCT07200089
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
NT-I7, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 9:02 PM EDT